Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.
Quick Facts
What This Study Found
[212Pb]Pb-DOTAMTATE showed superior tumor-to-kidney uptake ratio compared to other somatostatin receptor-targeting peptides, making it the most promising candidate for targeted alpha therapy of neuroendocrine tumors.
Key Numbers
Superior tumor-to-kidney AUC ratio for DOTAMTATE; DOTAM chelator had best chelation efficiency and fastest kinetics; compared DOTAMTATE, DOTATATE, JR11, and PSC-PEG2-TOC
How They Did This
Head-to-head preclinical comparison of four SSTR2-targeting peptides labeled with 212Pb. Chelation efficiency, pharmacokinetics, and biodistribution studied in AR42J tumor-bearing animals.
Why This Research Matters
Kidney damage limits how much radioactive peptide therapy can be given. A peptide that concentrates more in tumors and less in kidneys could allow higher, more effective doses.
What This Study Doesn't Tell Us
Animal model only. AR42J xenograft may not represent all human neuroendocrine tumors. 212Pb-specific dosimetry may differ from other radionuclides used clinically (e.g., 177Lu).
Trust & Context
- Original Title:
- Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.
- Published In:
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(3), 391-397 (2025)
- Authors:
- Saidi, Amal, Stallons, Tania A, Wong, Amy G, Schatzmann, Aaron T, Soysal, Ugur, Torgue, Julien J
- Database ID:
- RPEP-13368
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13368APA
Saidi, Amal; Stallons, Tania A; Wong, Amy G; Schatzmann, Aaron T; Soysal, Ugur; Torgue, Julien J. (2025). Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(3), 391-397. https://doi.org/10.2967/jnumed.124.268345
MLA
Saidi, Amal, et al. "Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.." Journal of nuclear medicine : official publication, 2025. https://doi.org/10.2967/jnumed.124.268345
RethinkPeptides
RethinkPeptides Research Database. "Side-by-Side Comparison of the In Vivo Performance of [212Pb..." RPEP-13368. Retrieved from https://rethinkpeptides.com/research/saidi-2025-sidebyside-comparison-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.